Neuronal N-type calcium channel blockers: A series of 4-piperidinylaniline analogs with analgesic activity

Drug Design and Discovery

Volumn 17, Issue 1, 2000, Pages 85-93

  Hu, Lain Yen ^a   Ryder, Todd R ^a   Rafferty, Michael F ^a   Siebers, Krista M ^a   Malone, Thomas ^a   Chatterjee, Arindam ^a   Feng, M Rose ^a   Lotarski, Susan M ^a   Rock, David M ^a   Stoehr, Sally J ^a   Taylor, Charles P ^a   Weber, Mark L ^a   Miljanich, George P ^b   Millerman, Elizabeth ^b   Szoke, Balazs G ^b  

^a PFIZER INC   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

N type calcium channel blockers

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PIPERIDINE DERIVATIVE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG CLEARANCE; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PAIN; PHYSICAL CHEMISTRY; STRUCTURE ANALYSIS; WRITHING TEST;

ANALGESICS, NON-NARCOTIC; ANILINE COMPOUNDS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6744268045     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. (a) Bowersox, S. S., Valentino, K. L. and Luther, R. R. (1994). Neuronal voltage sensitive calcium channels, Drug News and Perspectives, 7, 261-268;
2. (b) Scraibine, A. (1997). Calcium channel antagonists as neuroprotective agents. In: Neuroprotection: Fundamental and Clinical Aspects, edited by Bar, R.R. and Beal, M. F. pp. 27-51, New York: Marcel Dekker;
3. (c) Gilmore, J., Dell, C., Bowman, D. and Lodge, D. (1995). Neuronal calcium channels, Ann. Report. Med. Chem., 30, 51-60.
4. (a) Bowersox, S. S., Singh, T. and Luther, R. R. (1997). Selective blockade of N-type voltage-sensitive calcium channels protects against brain injury after transient focal cerebral ischemia in rats, Brain Res., 747, 343-347;
5. (b) Bowersox, S. S., Gadbois, T., Singh, T., Pettus, M., Wang, Y and Luther, R. R. (1996). Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain, J. Pharmacol. Exp. Ther., 279, 1243-1249;
6. (c) Verweij, B. H., Muizelaar, J. P., Winas, F. C., Peterson, P. L., Xiong, Y. and Lee, C. P. (1997). Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111), Neurological Res., 19, 334-339.
7. (a) Miljanich, G. P. and Ramachandran, J. (1995). Antagonists of neuronal calcium channels: structure, function, and therapeutic implications, Ann. Rev. Pharmacol. Toxicol., 35, 704-737;
8. (b) Olivera, B. M., Miljanich, G. P., Ramachandran, J., and Adam, M. E. (1994). Calcium channel diversity and neurotransmitter release: the ω-Conotoxins and ω-Agatoxins, Ann. Rev. Biochem., 63, 823-867;
9. (c) Pringle, A. K., Benham, C. D., Sim, L., Kennedy, S. J., Iannoti, F. and Sundstrom, L. E. (1996). Selective N-type calcium channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegeneration in organotypic hippocampal-slice cultures. Stroke, 27, 2124-2130.
10. Cox, B. and Denyer, J. C. (1998). N-type calcium channel blockers in pain and stroke, Exp. Opin. Ther. Patents, 8, 1237-1250.
11. Cohan, S. L., Redmond, D. J., Chen, M., Wilson, D. and Cyr, P. (1993). Flunarizine blocks elevation of free cytosolic calcium in synaptosomes following sustained depolarization. J. Cereb. Blood Flow Metab, 13, 947-954.
12. Grantham, C. J., Main, M. J. and Cannell, M. B (1994). Fluspirilene block of N-type calcium current in NGF-differentiated PC12 cells. Br. J. Pharmacol, 111, 483-488.
13. Yuen, P., Schelkun, R. M., Szoke, B. and Tarczy-Hornoch, K. (1998). Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg. Med. Chem. Lett, 8, 2415-2418.
14. Benham, C. D., Brown, T. H., Cooper, D. G., Evans, M. L., Harries, M. H., Herdon, H. J., Meakin, J. E., Murkitt, K. L. and Patel, S. R. (1993). SB 201823-A, a neuronal calcium antagonist is neuroprotective in two models of cerebral ischemia. Neuropharmacology, 32, 1249-1257.
15. Wood, N. I, Barone, F. C., Benham, C. D., Brown, T. H., Campbell, C. A., Cooper, D. G., Evans, M. L., Feuerstein, G. Z. and Hamilton, T. C. (1997). The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J. Cereb. Blood Flow Metab., 17, 421-429.
16. Barone, F. C., Price, W. J., Jakobsen, P., Sheardown, M. J. and Feuerstein, G. (1994). Pharmacological profile of a novel neuronal calcium-channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol, Biochem. Behav., 48, 77-85.
17. +2 current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br. J. Pharmacol., 122, 37-42;
18. +2 channel in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther., 280, 1184-1191.
19. Varming, T., Christophersen, P., Moeller, A., Peters, D., Axelsson, O. and Nielsen, E. O. (1996). Synthesis and biological activity of the neuronal calcium channel blocker 2-aminol-1-(2,5-dimethoxyphenyl-5-trifluoromethyl benzimidazole (NS-649). Bioorg. Med. Chem. Lett., 6, 245-248.
20. Bleakman, D., Boot, J., Dell, C., Gilmore, J., Harvey, J., Hotten, T. M., O'Brien, A. J., Palombo, L., Searez, A. S. and Tupper, D. E. (1998). Novel antagonists of neuronal (non-L-type) voltage-dependent calcium channels. 15th European Federation of Medicinal Chemistry International Symposium on Medicinal Chemistry, Edinburgh, Scotland, p 133.
21. Hu. L., Ryder, T. R., Rafferty, M. F., Feng, M. R , Lotarski, S. M., Rock, D. M., Sinz, M., Stoehr, S. J., Taylor, C. P., Weber, M. L., Bowersox, S. S., Miljanich, G. P., Millerman, E., Wang, Y. and Szoke, B. G (1999). Synthesis of a series of 4-benzyloxyaniline analogs as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic properties J. Med. Chem., 42, 4239-4249.
22. 16 was run in parallel as a standard in each assay.
23. (a) Malone, T. C., Booth, R. J., Campbell, G., Cody, W. L., Geer, J. J., He, J., Hu, L., Lescosky, L. J., Miljanich, G. P., Nadasdi, L., Rafferty, M. F, Rock, D. M., Sercel, A., Stoehr, S. J., Song, Y., Szoke, B. G., Tarczy-Hornoch, K., Taylor, C. P., Urge, L., Vartanian, M. G., Weber, M. L. and Yi, C. S. (1999). Identification and SAR studies of PD 151307, a novel N-type calcium channel blocker, Abstracts of Papers, 217th National Meeting of the American Chemical Society, Anaheim, CA, MEDI 122;
24. (b) Hu, L., Ryder, T. R., Cody. W. L., Lotarski, S. M., Millerman, E., Rafferty, M. F., Rock, D. M., Song, Y., Stoehr. S. J., Taylor, C. P., Weber, M. L., Szoke, B. G. and Vartanian, M. G. (1999). N,N-Dialkyldipeptidylamines as novel N-type calcium channel blockers, Bioorg. Med. Chem. Lett., 9, 907-912.
25. 21
26. The protocol of pharmacokinetic evaluation: Three Wistar rats received a 5 mg/kg bolus intravenous dose of the test compound as a solution and serial plasma samples were collected at various times up to 24 hr postdose. Plasma samples were analyzed using direct protein precipitation with acetonitrile and the compound was quantitated by Sciex LC/MS/MS system. A Betasil phenyl column (2.1 mm × 12cm) was used with a mobile phase of acetonitrile: 0.1% acetic acid (70:30, v/v).
27. 2+ channel currents in cultured rat superior cervical ganglion neurons, Drug Dev. Res., 41, 85-90.
28. 50 values are calculated using a four parameter logistic function.
29. (a) Clarke, F. H. and Cahoon, N. M. (1996). Partition Coefficients by Curve Fitting: The Use of Two Different Octanol Volumes in a Dual-Phase Potentiometric Titration. J. Pharm. Sci., 85, 178-83;
30. (b) Clarke, F. H. and Cahoon, N. M. (1995). Potentiometric Determination of the Partition and Distribution Coefficients of Dianionic Compounds. J. Pharm. Sci., 84, 53-4;
31. (c) Clarke, F. H. and Cahoon, N. M. (1987). Ionization constants by curve fitting: determination of partition and distribution coefficients of acids and bases and their ions. J. Pharm. Sci , 76, 611-20.